Scientific Abstracts (Table). Receiver operating characteristic curves showed that M-DAS28, DAS28 (CRP) and RAPID3 had higher predictive value (area under the curve) than CDAI or SDAI for radiographic progression at M12 and M24 (Table) . There was no impact of treatment arm on predictors of radiographic outcomes. Conclusions: In this post hoc analysis, disease activity scores at baseline according to M-DAS28, DAS28 (CRP) and RAPID3 were good predictors of radiographic progression at M12 and M24 and were more predictive than other measures of disease activity tested, with M-DAS28 demonstrating the greatest degree of prediction.
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Background: Rheumatoid Arthritis (RA) onset may occur at any age and peaks in the fifth decade. Because the mean age of general population is continually increasing and since older age could impact on outcomes, late-onset RA (LORA) will probably become a relevant issue for health care system in the next future. A better characterization of LORA could help rheumatologist in the therapeutic decision-making process tailored on the individual patient. Objectives: To investigate the relationship between age at disease onset and clinical, ultrasonographic and functional outcomes. . At baseline biological, functional and ultrasonographic data were recorded. The following items were compared at baseline and after 12 months from diagnosis: DAS28 CRP remission rate, functional disability using the Health Assessment Questionnaire (HAQ), power doppler (PWD) score, Methotrexate (MTX) treatment, use of glucocorticoids (GCs).
Results:
The main baseline demographic and disease characteristics of the whole sample of ERA (n=223) and the 3 age groups-YORA (46), IORA (81) and LORA (96)-are summarised in Table 1 . Age at RA-onset was independently associated with DAS28 CRP remission at 1 year (Table 2) . Conclusions: In a cohort of ERA, older age at disease onset is associated with a more active pattern disease at the beginning but with a greater probability of DAS28 CRP remission at 1 year. Background: The multi-biomarker disease activity (MBDA) test uses a validated algorithm with 12 serum protein biomarkers to assess disease activity in patients with RA. The MBDA score has previously been found to be a predictor of risk for radiographic progression (RP). Objectives: To evaluate data from six cohorts to collectively establish the relationship between the MBDA score and risk for RP. Methods: Clinical, MBDA score and radiographic data were analyzed for 6 cohorts with N>100: Leiden, SWEFOT Year 1, SWEFOT Year 2, OPERA Year 1, and AMPLE Year 1 (abatacept and adalimumab arms) (see Figure) . Analyses used published results when available or patient-level data when not (i.e., for Leiden; and for OPERA CRP analyses). Frequency of RP over one year was determined by category of MBDA score (low, moderate [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] , high on a scale of 1-100) at the start of the year for four cohorts and by category of MBDA score at the end of the year for AMPLE cohorts (as published). RP was defined using the threshold for change in total modified Sharp score ( mTSS) specific to each study (2 to >5 TSS units). Positive and negative predictive values (PPV and NPV) were determined for each study by comparing patients with high MBDA score (>44), DAS28-(ESR/CRP) (>5.1 or >4.09) or CRP (>3 mg/dL) vs. those in a not-high category. Relative risk (RR) for RP was determined for each study, and in a meta-analysis of the non-overlapping patient groups with MBDA scores available at the start of the year (Leiden, SWEFOT Year 1 and OPERA Year 1).
Results of multivariate analyses and analyses that combined MBDA score with other risk factors for RP were summarized. Results: The 6 study cohorts included patients receiving csDMARDs alone or with adalimumab, infliximab or abatacept. Overall rates of RP were 10-26%. In each study, RP was most frequent among patients with a high vs. not-high MBDA score (>44 vs. ≤44). For high MBDA scores, NPVs were 93-97% and PPVs were 18-32%, with RR values of 3.6-9.5 (P=0.002 to <0.0001) (Figure) . In a meta-analysis of the Leiden, SWEFOT Year 1 and OPERA Year 1 cohorts, RR was 5.1 (P<0.0001) for MBDA categories, and 1.4 (P=0.23) and 1.6 (P=0.01) for categories of DAS28-CRP or CRP, respectively. Previously published multivariate analyses in the Leiden and SWEFOT Year 1 cohorts showed that MBDA score was an independent predictor of RP compared with other predictors. In the Leiden cohort, MBDA score was the strongest predictor and high MBDA score
